• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

贝叶斯多元逻辑回归在可观测治疗异质性下的优越性和劣性决策。

Bayesian Multivariate Logistic Regression for Superiority and Inferiority Decision-Making under Observable Treatment Heterogeneity.

机构信息

Department of Methodology and Statistics, Tilburg University.

Department of Theory, Methodology and Statistics, Open University of the Netherlands.

出版信息

Multivariate Behav Res. 2024 Jul-Aug;59(4):859-882. doi: 10.1080/00273171.2024.2337340. Epub 2024 May 11.

DOI:10.1080/00273171.2024.2337340
PMID:38733304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11548885/
Abstract

The effects of treatments may differ between persons with different characteristics. Addressing such treatment heterogeneity is crucial to investigate whether patients with specific characteristics are likely to benefit from a new treatment. The current paper presents a novel Bayesian method for superiority decision-making in the context of randomized controlled trials with multivariate binary responses and heterogeneous treatment effects. The framework is based on three elements: a) Bayesian multivariate logistic regression analysis with a Pólya-Gamma expansion; b) a transformation procedure to transfer obtained regression coefficients to a more intuitive multivariate probability scale (i.e., success probabilities and the differences between them); and c) a compatible decision procedure for treatment comparison with prespecified decision error rates. Procedures for a priori sample size estimation under a non-informative prior distribution are included. A numerical evaluation demonstrated that decisions based on a priori sample size estimation resulted in anticipated error rates among the trial population as well as subpopulations. Further, average and conditional treatment effect parameters could be estimated unbiasedly when the sample was large enough. Illustration with the International Stroke Trial dataset revealed a trend toward heterogeneous effects among stroke patients: Something that would have remained undetected when analyses were limited to average treatment effects.

摘要

治疗效果可能因个体特征不同而有所差异。解决这种治疗异质性问题至关重要,因为它可以帮助我们研究具有特定特征的患者是否可能从新的治疗方法中获益。本文提出了一种新的贝叶斯方法,用于在具有多元二分类响应和异质治疗效果的随机对照试验中进行优势决策。该框架基于三个要素:a)贝叶斯多元逻辑回归分析与 Pólya-Gamma 扩展;b)一种转换过程,将获得的回归系数转换为更直观的多元概率尺度(即成功概率及其差异);c)一种与预设决策错误率兼容的治疗比较决策过程。还包括在非信息先验分布下进行先验样本量估计的程序。数值评估表明,基于先验样本量估计的决策在试验人群和亚人群中产生了预期的错误率。此外,当样本足够大时,可以无偏估计平均和条件治疗效果参数。对国际卒中试验数据集的说明揭示了卒中患者之间存在治疗效果异质性的趋势:当分析仅限于平均治疗效果时,这种趋势可能会被忽略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac71/11548885/b0f26fb7ef6b/HMBR_A_2337340_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac71/11548885/58e72963513a/HMBR_A_2337340_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac71/11548885/3b0caffda246/HMBR_A_2337340_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac71/11548885/b0f26fb7ef6b/HMBR_A_2337340_F0003_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac71/11548885/58e72963513a/HMBR_A_2337340_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac71/11548885/3b0caffda246/HMBR_A_2337340_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac71/11548885/b0f26fb7ef6b/HMBR_A_2337340_F0003_B.jpg

相似文献

1
Bayesian Multivariate Logistic Regression for Superiority and Inferiority Decision-Making under Observable Treatment Heterogeneity.贝叶斯多元逻辑回归在可观测治疗异质性下的优越性和劣性决策。
Multivariate Behav Res. 2024 Jul-Aug;59(4):859-882. doi: 10.1080/00273171.2024.2337340. Epub 2024 May 11.
2
Bayesian multilevel multivariate logistic regression for superiority decision-making under observable treatment heterogeneity.基于可观测处理异质性的优势决策的贝叶斯多层多变量逻辑回归。
BMC Med Res Methodol. 2023 Oct 5;23(1):220. doi: 10.1186/s12874-023-02034-z.
3
A Bayesian non-inferiority approach using experts' margin elicitation - application to the monitoring of safety events.一种使用专家边际推断的贝叶斯非劣效性方法 - 在安全事件监测中的应用。
BMC Med Res Methodol. 2019 Sep 18;19(1):187. doi: 10.1186/s12874-019-0826-5.
4
Implementing a decision-theoretic design in clinical trials: why and how?在临床试验中实施决策理论设计:为何以及如何实施?
Stat Med. 2007 Nov 30;26(27):4939-57. doi: 10.1002/sim.2949.
5
Estimating the Sampling Distribution of Posterior Decision Summaries in Bayesian Clinical Trials.贝叶斯临床试验中后验决策总结的抽样分布估计。
Biom J. 2024 Dec;66(8):e70002. doi: 10.1002/bimj.70002.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Using full probability models to compute probabilities of actual interest to decision makers.使用全概率模型来计算决策者实际感兴趣的概率。
Int J Technol Assess Health Care. 2001 Winter;17(1):17-26. doi: 10.1017/s0266462301104034.
8
Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.在采用经典与贝叶斯混合方法的优效性临床试验中,用于二元反应的样本量确定。
Trials. 2017 Feb 23;18(1):83. doi: 10.1186/s13063-017-1791-0.
9
Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.用于II期药物筛选试验的多臂多阶段贝叶斯设计评估——血液肿瘤学中的一个例子
BMC Med Res Methodol. 2016 Jun 2;16:67. doi: 10.1186/s12874-016-0166-7.
10
Decision-making with multiple correlated binary outcomes in clinical trials.临床试验中具有多个相关二元结局的决策制定。
Stat Methods Med Res. 2020 Nov;29(11):3265-3277. doi: 10.1177/0962280220922256. Epub 2020 Jul 16.

引用本文的文献

1
Bayesian multilevel multivariate logistic regression for superiority decision-making under observable treatment heterogeneity.基于可观测处理异质性的优势决策的贝叶斯多层多变量逻辑回归。
BMC Med Res Methodol. 2023 Oct 5;23(1):220. doi: 10.1186/s12874-023-02034-z.

本文引用的文献

1
A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint.关于二分类结局随机试验中个体治疗效果预测的教程。
Stat Med. 2021 Nov 20;40(26):5961-5981. doi: 10.1002/sim.9154. Epub 2021 Aug 16.
2
Covariate adjustment in subgroup analyses of randomized clinical trials: A propensity score approach.随机临床试验亚组分析中的协变量调整:倾向评分法。
Clin Trials. 2021 Oct;18(5):570-581. doi: 10.1177/17407745211028588. Epub 2021 Jul 16.
3
Decision-making with multiple correlated binary outcomes in clinical trials.
临床试验中具有多个相关二元结局的决策制定。
Stat Methods Med Res. 2020 Nov;29(11):3265-3277. doi: 10.1177/0962280220922256. Epub 2020 Jul 16.
4
Bayesian cancer clinical trial designs with subgroup-specific decisions.贝叶斯癌症临床试验设计与亚组特异性决策。
Contemp Clin Trials. 2020 Mar;90:105860. doi: 10.1016/j.cct.2019.105860. Epub 2019 Oct 31.
5
Bayes factors for superiority, non-inferiority, and equivalence designs.优效性、非劣效性和等效性设计的贝叶斯因子。
BMC Med Res Methodol. 2019 Mar 29;19(1):71. doi: 10.1186/s12874-019-0699-7.
6
Sample size considerations and predictive performance of multinomial logistic prediction models.多分类逻辑回归预测模型的样本量考虑因素和预测性能。
Stat Med. 2019 Apr 30;38(9):1601-1619. doi: 10.1002/sim.8063. Epub 2019 Jan 6.
7
Methods for the analysis of multiple endpoints in small populations: A review.小群体中多个终点指标的分析方法:综述
J Biopharm Stat. 2019;29(1):1-29. doi: 10.1080/10543406.2018.1489402. Epub 2018 Jul 9.
8
Three Insights from a Bayesian Interpretation of the One-Sided Value.对单边值的贝叶斯解释的三点见解。
Educ Psychol Meas. 2017 Jun;77(3):529-539. doi: 10.1177/0013164416669201. Epub 2016 Oct 5.
9
Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.生物统计学教程:临床试验中数据驱动的亚组识别与分析
Stat Med. 2017 Jan 15;36(1):136-196. doi: 10.1002/sim.7064. Epub 2016 Aug 3.
10
Utility-based designs for randomized comparative trials with categorical outcomes.用于具有分类结局的随机对照试验的基于效用的设计。
Stat Med. 2016 Oct 30;35(24):4285-4305. doi: 10.1002/sim.6989. Epub 2016 May 18.